Long-Term Real-World Outcomes of Tenofovir Alafenamide in Chronic Hepatitis B: Detailed Analysis of Treatment-Naive and Experienced Patients
The Korean Journal of Gastroenterology · 2025
DOI: 10.4166/kjg.2024.140 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Korean Journal of Gastroenterology, 2025. Verfasst von Yu-Xuan Song und 4 weiteren Autor:innen. Beteiligte Einrichtung: Peking University People's Hospital, Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseas…. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Antiviral Agents, Tenofovir, Adenine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Major Project during the 13th Five-Year Plan Period, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background/Aims: This study assessed the long-term efficacy and safety of tenofovir alafenamide (TAF) in real-world settings.
Methods
Patients who were candidates for TAF treatment and were followed up at 12-week intervals over 192 weeks were enrolled in this study.
Results
One hundred and forty-four patients (50 treatment-naive and 94 treatment-experienced) were included in this study. The cumulative incidence rates of cirrhosis and hepatocellular carcinoma at 192 weeks were 3.9% and 0.7%, respectively. In treatment- naive patients, the rates of a virological response, HBeAg conversion, and HBsAg loss at 192 weeks were 100%, 33.3%, and 2%, respectively. The treatment-naive patients exhibited higher baseline HBsAg levels than the treatment-experienced patients (4.31 log10IU/mL vs. 3.97 log10IU/mL). A significant decrease in the HBsAg levels from the baseline was observed at 144 and 192 weeks in the treatment-naive patients (p=0.01). The baseline body mass index (BMI)
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Peking University People's Hospital, Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology…
ORCID-Profile: Yan-Di Xie
Förderung
- National Major Project during the 13th Five-Year Plan Period
- National Natural Science Foundation of China
Zitieren
APA
Song, Y. X., Song, G. J., Ma, H., Feng, B., & Xie, Y. D. (2025). Long-Term Real-World Outcomes of Tenofovir Alafenamide in Chronic Hepatitis B: Detailed Analysis of Treatment-Naive and Experienced Patients. The Korean Journal of Gastroenterology. https://doi.org/10.4166/kjg.2024.140
Vancouver
Song YX, Song GJ, Ma H, Feng B, Xie YD. Long-Term Real-World Outcomes of Tenofovir Alafenamide in Chronic Hepatitis B: Detailed Analysis of Treatment-Naive and Experienced Patients. The Korean Journal of Gastroenterology. 2025. doi:10.4166/kjg.2024.140
BibTeX
@article{Song2025,
author = {Song, Yu-Xuan and Song, Guang-Jun and Ma, Hui and Feng, Bo and Xie, Yan-Di},
title = {Long-Term Real-World Outcomes of Tenofovir Alafenamide in Chronic Hepatitis B: Detailed Analysis of Treatment-Naive and Experienced Patients},
journal = {The Korean Journal of Gastroenterology},
year = {2025},
doi = {10.4166/kjg.2024.140}
}
EUVIMED